Opinion|Videos|July 8, 2024
Frontline BTKi Selection
Key opinion leaders examine the use of continuous Bruton's tyrosine kinase inhibitor therapy in front-line treatment, strategies for sequencing therapies, and the potential incorporation of obinutuzumab into treatment regimens.
Advertisement
Episodes in this series
- Dr Lamanna: When considering continuous BTKi therapy in the front-line setting, how do you select among available treatment options?
- How do you select patients for acala vs zanu?
- In which patients would you consider the addition of obinutuzumab?
- Dr Danilov: How important is long-term efficacy and safety data when making informed treatment decisions and how may these data shape your overall treatment approach?
- Dr Coombs asks about Frontline use??
- ELEVATE-TN – 6-yr follow up (Sharman, et al. ASH 2023. Abstract 636)
- SEQUOIA – Extended Follow-up (Munir, et al. Hemasphere 2023)
Advertisement
Related to this article
The top 5 OncLive TV videos of the week.
Read a refresh of hematologic cancer FDA and global regulatory news from September 2026.
The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.
The FDA has approved pirtobrutinib for the treatment of adult patients with previously untreated CLL or SLL harboring no known 17p deletion.
Advertisement
Advertisement
Trending on OncLive
1
CHMP Recommends Approval of Daraxonrasib for Previously Treated Metastatic Pancreatic Cancer
2
Stay Ahead of ESMO 2026: See What Lung Cancer Experts Are Prioritizing
3
Lifileucel Linked to Low Rates of Post-Discharge Severe TRAEs, Readmissions in Advanced Melanoma
4
Refined ADC Development Helps Weigh Biomarker-Based Decisions and Treatment Sequencing in Gynecologic Cancers
5